Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results From a Phase 3 Trial, Future 2
Document Type
Abstract
Publication Date
June 2017
DOI
10.1136/annrheumdis-2017-eular.1274
Journal Title
Annals of the Rheumatic Diseases
Department
Dermatology
Recommended Citation
McInnes, I., Mease, P., Ritchlin, C., Rahman, P., Gottlieb, A., Kirkham, B., Kajekar, R., Delicha, E., Pricop, L., Mpofu, S., & Future 2 Study Grp, F. (2017). Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results From a Phase 3 Trial, Future 2. Annals of the Rheumatic Diseases, 76 (Suppl 2), 145. https://doi.org/10.1136/annrheumdis-2017-eular.1274
COinS
